EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways

Keith L Knutson iD

The Journal of Immunology · 01.05.2024 · 212 (9) · 1397-1405

DOI: 10.4049/jimmunol.2300674 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Immunology, online erschienen am 01.05.2024. Verfasst von Keith L Knutson. Beteiligte Einrichtung: Mayo Clinic, Jacksonville, FL. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, DOD CDMRP Breast Cancer Research Program, HHS | NIH | National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of immune checkpoint blockade therapy has revolutionized cancer treatments and is partly responsible for the significant decline in cancer-related mortality observed during the last decade. Immune checkpoint inhibitors, such as anti–programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), have demonstrated remarkable clinical successes in a subset of cancer patients. However, a considerable proportion of patients remain refractory to immune checkpoint blockade, prompting the exploration of mechanisms of treatment resistance. Whereas much emphasis has been placed on the role of PD-L1 and PD-1 in regulating the activity of tumor-infiltrating T cells, recent studies have now shown that this immunoregulatory axis also directly regulates myeloid cell activity in the tumor microenvironment including tumor-infiltrating dendritic cells. In this review, I discuss the most recent advances in the understanding of how PD-1, PD-L1, and programmed cell death ligand 2 regulate the function of tumor-infiltrating dendritic cells, emphasizing the need for further mechanistic studies that could facilitate the development of novel combination immunotherapies for improved cancer patient benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorLigandsApoptosisDendritic CellsTumor Microenvironment

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorLigands

Autor:innen und Institutionen

  • Mayo Clinic, Jacksonville, FL.

ORCID-Profile: Keith L Knutson

Förderung

  • NCI NIH HHS
  • DOD CDMRP Breast Cancer Research Program
  • HHS | NIH | National Cancer Institute
  • Susan G. Komen

Zitieren

APA

Knutson, K. L. (2024). Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways. The Journal of Immunology, 212(9), 1397-1405. https://doi.org/10.4049/jimmunol.2300674

Vancouver

Knutson KL. Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways. The Journal of Immunology. 2024;212(9):1397-1405. doi:10.4049/jimmunol.2300674

BibTeX
@article{Knutson2024,
  author = {Knutson, Keith L},
  title = {Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways},
  journal = {The Journal of Immunology},
  year = {2024},
  volume = {212},
  number = {9},
  pages = {1397--1405},
  doi = {10.4049/jimmunol.2300674}
}
Kostenlos starten →